CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

被引:134
作者
Adachi, K [1 ]
Katsube, T [1 ]
Kawamura, A [1 ]
Takashima, T [1 ]
Yuki, M [1 ]
Amano, K [1 ]
Ishihara, S [1 ]
Fukuda, R [1 ]
Watanabe, M [1 ]
Kinoshita, Y [1 ]
机构
[1] Shimane Med Univ, Dept Internal Med 2, Izumo, Shimane 6938501, Japan
关键词
D O I
10.1046/j.1365-2036.2000.00840.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: CYP2C19 has an important role in the catabolism of several proton pump inhibitors. However, the relative contribution of CYP2C19-mediated metabolism varies among the different proton pump inhibitors. Aim: To determine the effect of CYP2C19 genotype status on intragastric pH during dosing with lansoprazole or rabeprazole. Subjects and methods: The subjects were 20 male volunteers without Helicobacter pylori infection. Their CYP2C19 genotype status was determined by a polymerase chain reaction-restriction fragment length polymorphism method. Twenty-four-hour monitoring of intragastric acidity was performed three times: once without medication, once on the last day of a 7-day course of rabeprazole, and once on the last day of a 7-day course of lansoprazole. Results: Subjects were divided into three groups on the basis of their CYP2C19 genotype status: homozygous extensive metabolizers (homo-EMs, n=7), heterozygous extensive metabolizers (hetero-EMs, n=9), and poor metabolizers (PMs, n=4). The median pH during rabeprazole administration was not influenced by CYP2C19 genotype. On the other hand, the median pH in PMs during lansoprazole dosing was higher than in homo-EMs and hetero-EMs. The percentage of time with pH < 4.0 had a similar tendency to that of median pH. Conclusion: CYP2C19 genotype status influences gastric acid suppression by lansoprazole, but not by rabeprazole.
引用
收藏
页码:1259 / 1266
页数:8
相关论文
共 47 条
  • [1] Pharmacokinetics, metabolism and interactions of acid pump inhibitors - Focus on omeprazole, lansoprazole and pantoprazole
    Andersson, T
    [J]. CLINICAL PHARMACOKINETICS, 1996, 31 (01) : 9 - 28
  • [2] Aoyama N, 1999, J GASTROENTEROL, V34, P80
  • [3] RELATIONSHIP OF HELICOBACTER-PYLORI TO SERUM PEPSINOGENS IN AN ASYMPTOMATIC JAPANESE POPULATION
    ASAKA, M
    KIMURA, T
    KUDO, M
    TAKEDA, H
    MITANI, S
    MIYAZAKI, T
    MIKI, K
    GRAHAM, DY
    [J]. GASTROENTEROLOGY, 1992, 102 (03) : 760 - 766
  • [4] ROLE OF GASTRIC-ACID SUPPRESSION IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE
    BELL, NJV
    HUNT, RH
    [J]. GUT, 1992, 33 (01) : 118 - 124
  • [5] PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN
    BERTILSSON, L
    LOU, YQ
    DU, YL
    LIU, Y
    KUANG, TY
    LIAO, XM
    WANG, KY
    REVIRIEGO, J
    ISELIUS, L
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) : 388 - 397
  • [6] DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
  • [7] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
  • [8] Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans
    Edeki, TI
    Goldstein, JA
    deMorais, SMF
    Hajiloo, L
    Butler, M
    Chapdelaine, P
    Wilkinson, GR
    [J]. PHARMACOGENETICS, 1996, 6 (04): : 357 - 360
  • [9] Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
    Furuta, T
    Ohashi, K
    Kamata, T
    Takashima, M
    Kosuge, K
    Kawasaki, T
    Hanai, H
    Kubota, T
    Ishizaki, T
    Kaneko, E
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) : 1027 - 1030
  • [10] CΥP2C19 genotype status and effect of omeprazole on intragastric pH in humans
    Furuta, T
    Ohashi, K
    Kosuge, K
    Zhao, XJ
    Takashima, M
    Kimura, M
    Nishimoto, M
    Hanai, H
    Kaneko, E
    Ishizaki, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) : 552 - 561